Pharmaceutical Substances - Version 4.8
The version 4.8 of Pharmaceutical Substances was launched in May 2020.
Pharmaceutical Substances 4.8 contains 16 new APIs and a total of 43,444 structures, 12,541 reactions, and 2,750 active pharmaceutical ingredients.
Additionally, the following APIs have been updated:
Statement by the authors Prof. Axel Kleemann, Prof. Bernhard Kutscher and Dr. Dietmar Reichert
"This spring release covers 16 new APIs and presents quite a few first-in-class drug products with innovative mechanism of action as well as fast track or breakthrough designation.
Amongst them Remdesivir, an antiviral RNA polymerase inhibitor studied against Ebola and Corona viruses. This month US-FDA and Japan granted Gilead Sciences an emergency use authorization of Remdesivir to be distributed and used by licensed health care providers to treat hospitalized patients with severe COVID-19.
Promising new kinase inhibitors were approved with Entrectinib against non-small-cell lung cancer and Zanubrutinib for treatment of mantle cell lymphoma.
Furthermore the update contains Avapritinib for treatment of tumors with rare mutations and Tazemetostat, an EZH2 methyltransferase inhibitor, as oncology drugs. The JAK inhibitors Fedratinib and Upadacitinib were launched for treatment of myelofibrosis and rheumatoid arthritis, respectively.
Breakthrough designation also received two new CNS drugs with the steroid Brexanolone against postpartum depression and Pitolisant for treatment of excessive daytime sleepiness in people with narcolepsy.
In addition this release also describes the peptide Afamelanotide for treatment of photoxicity in people with erythropoietic protoporphyria, Voxelotor against sickle cell disease as well as Triclabendazole, Levoleucovorin, Amphetamine, Dextroamfetamine, Lisdexamfetamine and further updates."